Search
Filter Results
- Resource Type
- Book2
- Article1
- Atlases, Pictorial1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Cancer Treat Rep1
Search Results
Sort by
- BookLaura Nabarro, Stephen Morris-Jones, David A.J. Moore.Contents:
Arthropod-borne diseases
Infections acquired through the gastrointestinal tract
Infections acquired by airborne transmission
Ectoparasites
Bites, stings, venoms, toxins
Nutrition
Non-communicable disease
Disease of unusual or uncertian aetiology.Digital Access ClinicalKey 2019 - ArticleCabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ.Cancer Treat Rep. 1978 Mar;62(3):425-8.Maytansine, a new ansa macrolide antitumor antibiotic, was administered to 60 patients as part of a phase I study. The doses given ranged from 0.01 (starting level) to 0.9 mg/m2 for 3 days. The toxic effects encountered consisted principally of nausea, vomiting, diarrhea, and occasionally, stomatitis and alopecia. Superficial phlebitis was also encountered and occurred when the drug was diluted in a volume of less than 250 ml. Myelosuppression occurred infrequently; it was almost regularly associated with abnormal liver function tests. Antitumor activity was detected in one patient each with melanoma, breast carcinoma; and head and neck clear cell carcinoma. Further studies are indicated with this compound since it has shown evidence of activity with little or no myelosuppression.